- Home
- ACIU vs FT Comparison
ACIU vs FT Comparison
Compare ACIU & FT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIU
- FT
- Stock Information
- Founded
- ACIU 2003
- FT 1988
- Country
- ACIU Switzerland
- FT United States
- Employees
- ACIU N/A
- FT N/A
- Industry
- ACIU Biotechnology: Pharmaceutical Preparations
- FT Trusts Except Educational Religious and Charitable
- Sector
- ACIU Health Care
- FT Finance
- Exchange
- ACIU Nasdaq
- FT Nasdaq
- Market Cap
- ACIU 213.3M
- FT 192.5M
- IPO Year
- ACIU 2016
- FT N/A
- Fundamental
- Price
- ACIU $2.14
- FT $8.00
- Analyst Decision
- ACIU Strong Buy
- FT
- Analyst Count
- ACIU 1
- FT 0
- Target Price
- ACIU $12.00
- FT N/A
- AVG Volume (30 Days)
- ACIU 162.6K
- FT 63.0K
- Earning Date
- ACIU 08-05-2025
- FT 01-01-0001
- Dividend Yield
- ACIU N/A
- FT 7.85%
- EPS Growth
- ACIU N/A
- FT N/A
- EPS
- ACIU N/A
- FT N/A
- Revenue
- ACIU $36,362,036.00
- FT N/A
- Revenue This Year
- ACIU N/A
- FT N/A
- Revenue Next Year
- ACIU $533.21
- FT N/A
- P/E Ratio
- ACIU N/A
- FT N/A
- Revenue Growth
- ACIU 86.71
- FT N/A
- 52 Week Low
- ACIU $1.43
- FT $5.97
- 52 Week High
- ACIU $3.98
- FT $7.23
- Technical
- Relative Strength Index (RSI)
- ACIU 49.10
- FT 74.24
- Support Level
- ACIU $2.05
- FT $7.73
- Resistance Level
- ACIU $2.50
- FT $7.85
- Average True Range (ATR)
- ACIU 0.20
- FT 0.06
- MACD
- ACIU -0.03
- FT 0.01
- Stochastic Oscillator
- ACIU 20.00
- FT 93.38
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About FT Franklin Universal Trust
Franklin Universal Trust is a closed-end management investment company. Its primary investment objective is to provide high, current income consistent with the preservation of capital. Its secondary objective is the growth of income through dividend increases and capital appreciation. The fund invests in two asset classes being the high yield bonds and utility stocks.